Targeted radiation and immunotherapy join forces against Hard-to-Treat lung cancer

NCT ID NCT07689643

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-phase trial tests a new combination treatment for people with a specific type of advanced lung cancer (non-small cell lung cancer) that has spread and shows a marker called FAP on scans. The treatment pairs a targeted radiation drug (177Lu-RTX-2358) with a standard immunotherapy (PD-1 inhibitor). The goal is to see if the combination is safe, where the radiation goes in the body, and whether it can shrink tumors. The study enrolls about 36 adults whose cancer has not responded to prior treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177-labeled RTX-2358 (a targeted radiation drug) plus a PD-1 inhibitor (immunotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific type of advanced lung cancer that is hard to treat.
What could go wrong: This is a very early, small study (36 people) focused on safety, not proof of effectiveness. The treatment involves radiation and may cause side effects; it may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Union Hospital, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.